Chemoradiation treatment patterns among United States Veteran Health Administration patients with unresectable stage III non-small cell lung cancer

[1]  Chan Kwon Park,et al.  Impact of smoking amount on clinicopathological features and survival in non-small cell lung cancer , 2020, BMC cancer.

[2]  Xin Wang,et al.  The impact of age on the survival outcomes and risk of radiation pneumonitis in patients with unresectable locally advanced non-small cell lung cancer receiving chemoradiotherapy , 2020, Journal of thoracic disease.

[3]  I. Cotarla,et al.  Treatment Decision Drivers in Stage III Non-Small-Cell Lung Cancer: Outcomes of a Web-Based Survey of Oncologists in the United States. , 2020, JCO oncology practice.

[4]  M. Duh,et al.  Predictors of chemoradiotherapy versus single modality therapy and overall survival among patients with unresectable, stage III non-small cell lung cancer , 2020, PloS one.

[5]  A. Sakin,et al.  The effect of different treatment modalities on survival in elderly patients with locally advanced non-small cell lung cancer. , 2019, Pulmonology.

[6]  D. Carbone,et al.  Racial/Ethnic Disparities in the Delivery of Curative Intent Therapy in Patients with Stage III Non-small Cell Lung Cancer Not Treated Surgically: An Analysis of the National Cancer Database , 2018, International Journal of Radiation Oncology*Biology*Physics.

[7]  Corinne M. Graffunder,et al.  Tobacco Product Use Among Military Veterans — United States, 2010–2015 , 2018, MMWR. Morbidity and mortality weekly report.

[8]  L. ZulligLeah,et al.  Cancer Incidence Among Patients of the U.S. Veterans Affairs Health Care System: 2010 Update , 2017 .

[9]  M. Janssen-Heijnen,et al.  Stage III Non-Small Cell Lung Cancer in the elderly: Patient characteristics predictive for tolerance and survival of chemoradiation in daily clinical practice. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[10]  P. Selby,et al.  The prevalence and outcomes of frailty in older cancer patients: a systematic review. , 2015 .

[11]  M. Kelley,et al.  Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration data. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  G. Michaud,et al.  Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. , 2013, Chest.

[13]  J. Niland,et al.  Smoking status and survival in the national comprehensive cancer network non–small cell lung cancer cohort , 2013, Cancer.

[14]  N. Saijo,et al.  Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). , 2012, The Lancet. Oncology.

[15]  L. Walter,et al.  Impact of age and comorbidity on non-small-cell lung cancer treatment in older veterans. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Benjamin Movsas,et al.  Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. , 2011, Journal of the National Cancer Institute.

[17]  N. O'Rourke,et al.  Concurrent chemoradiotherapy in non-small cell lung cancer. , 2010, The Cochrane database of systematic reviews.

[18]  Jose Belderbos,et al.  Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Hiroshi Okazaki,et al.  Never‐smoking nonsmall cell lung cancer as a separate entity , 2008, Cancer.

[20]  M. Socinski,et al.  Dose‐escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma , 2001, Cancer.

[21]  W. Curran,et al.  Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. , 2001, Chest.

[22]  P M Layde,et al.  Are patients at Veterans Affairs medical centers sicker? A comparative analysis of health status and medical resource use. , 2000, Archives of internal medicine.

[23]  W. Curran,et al.  Final Results of Phase III Trial in Regionally Advanced Unresectable Non-Small Cell Lung Cancer : Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group , 2000 .

[24]  S. Kudoh,et al.  Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Herndon,et al.  Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. , 1996, Journal of the National Cancer Institute.

[26]  R. Arriagada,et al.  Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. , 1991, Journal of the National Cancer Institute.

[27]  K. Propert,et al.  A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. , 1990, The New England journal of medicine.

[28]  A. Ganti,et al.  Effect of smoking on survival from non-small cell lung cancer: a retrospective Veterans’ Affairs Central Cancer Registry (VACCR) cohort analysis , 2014, Medical Oncology.

[29]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..